P 011
Alternative Names: P-011Latest Information Update: 21 Nov 2024
Price :
$50 *
At a glance
- Originator Abbisko Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Non-small cell lung cancer
Most Recent Events
- 17 Oct 2024 Early research in Non-small cell lung cancer in China (unspecified route) (Abbisko Therapeutics pipeline; October 2024)